A comprehensive view of Amneal Pharmaceuticals LLC. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Amneal recalls four lots of generic vancomycin hydrochloride in pack sizes 80 mL, 300 mL and 150 mL due to potential overfilling during manufacturing; error could result in excessive dosing
Published: March 29, 2024 by FiercePharma
FTC files an amicus brief alleging that Teva improperly listed patents on its ProAir HFA asthma inhaler in the FDA Orange Book, blocking Amneal's approval for a generic version; the FTC is seeking a court judgement to make Teva retract the patents
Published: March 25, 2024 by FiercePharma
Amneal reports it launched 39 new retail and injectable products in 2023, including 13 in Q4 2023; new products include potassium phosphate vials, tranexamic acid and esmolol intravenous bags, spironolactone suspension with 180-day exclusivity and others
Published: January 05, 2024 by Business Wire
Amneal gets FDA approval for injectable calcium gluconate in sodium chloride, 1000 mg/50 mL and 2000 mg/100 mL, a drug on the FDA shortage list; the firm also received a Competitive Generic Therapy approval designation with 180-day exclusivity
Published: September 07, 2023 by Business Wire
FDA denies approval for Amneal's IPX203, an oral formulation to treat Parkinson’s disease due to inadequate safety data; the rejection affects Amneal’s goal for a midyear launch with potential peak sales opportunity of US$500M in the US
Published: July 06, 2023 by FiercePharma

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count